Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Perjeta
Pharma
FDA approves AZ/Daiichi's Enhertu in 1st-line breast cancer
The FDA has approved Enhertu combined with Roche’s Perjeta as a first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Kevin Dunleavy
Dec 15, 2025 4:15pm
Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod
Nov 14, 2025 10:52am
ASCO: AZ, Daiichi flex Enhertu muscle in 2 cancers
Jun 2, 2025 8:00am
Roche bolsters Perjeta's case with ten-year breast cancer data
May 13, 2025 11:23am
Enhertu drives strong efficacy in first-line breast cancer
Apr 21, 2025 10:12am
Roche settles UPenn patent lawsuit over breast cancer drugs
Mar 14, 2025 3:00pm
